Evidence map›Paper›PMID 36720287›Full record

ArticleThe Journal of allergy and clinical immunology2023

Lung-resident CD69

Takao Kobayashi, Koji Iijima, Koji Matsumoto, Jyoti K Lama, Hirohito Kita

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CCR8The Journal of allergy and clinical immunology · 2026
    Article
  5. Review
  6. TLR4Nature communications · 2025
    Article
  7. Review
  8. Article
  9. Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025
    Review
  10. Article
  11. Review
  12. Update on type 2 immunity.The Journal of allergy and clinical immunology · 2025
    Review
  13. Review
  14. Control of Asthma and Allergy by Regulatory T Cells.International archives of allergy and immunology · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Tissue-Resident Memory T Cells in Allergy.Clinical reviews in allergy & immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Takao KobayashiDivision of Allergic Diseases, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
Koji IijimaDivision of Allergic Diseases, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
Koji MatsumotoDivision of Allergic Diseases, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
Jyoti K LamaImmunology Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester and Scottsdale, Rochester, Minn.
Hirohito KitaDivision of Allergic Diseases, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic, Scottsdale, Ariz; Department of Immunology, Mayo Clinic, Rochester, and Mayo Clinic, Scottsdale, Ariz. Electronic address: kita.hirohito@mayo.edu.
WinnMed · USMayo Clinic in Arizona · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Mechanisms of IL-33 secretion in allergic diseasesR01AI128729 · NIAID · MAYO CLINIC ROCHESTER · PI Hirohito Kita, SCOTT M. O'GRADY · 2017 to 2026
$5.6M
Mechanisms of Allergen-induced Type 2 ImmunityR37AI071106 · NIAID · MAYO CLINIC ROCHESTER · PI Hirohito Kita · 2018 to 2026
$5.2M
NCI NIH HHS P30 CA015083NIAID NIH HHS R01 AI128729NIAID NIH HHS R37 AI071106
6 · The paper itself

Abstract

backgroundChronic airway diseases such as asthma are characterized by persistent type 2 immunity in the airways. We know little about the mechanisms that explain why type 2 inflammation continues in these diseases.

objectiveWe used mouse models to investigate the mechanisms involved in long-lasting immune memory.

methodsNaive mice were exposed intranasally to ovalbumin (OVA) antigen with Alternaria extract as an adjuvant. Type 2 memory was analyzed by parabiosis model, flow cytometry with in vivo antibody labeling, and intranasal OVA recall challenge. Gene-deficient mice were used to analyze the mechanisms.

resultsIn the parabiosis model, mice previously exposed intranasally to OVA with Alternaria showed more robust antigen-specific immune responses and airway inflammation than mice with circulating OVA-specific T cells. After a single airway exposure to OVA with Alternaria, CD69

conclusionCD69

Indexed as

AsthmaInterleukin-33AllergensAnimalsCytokinesDisease Models, AnimalInflammationInterleukin-1 Receptor-Like 1 ProteinLungMiceMice, Inbred BALB COvalbuminTh2 CellsAllergensCytokinesInterleukin-1 Receptor-Like 1 ProteinInterleukin-33OvalbuminallergensallergyIL-33IL-5T(H)2 cellstissue-resident memory T cells

Identifiers

PMID36720287
PMCPMC10330297
OpenAlexW4318320629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.